Subscribe Back to Results Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States October 20, 2014 | Joseph Mallon, Ph.D.Ryan E. Melnick, Ph.D.Kimberly J. Miller, Ph.D.Agnes Juang, Ph.D.William ZimmermanJane Dai, Ph.D.Nathanael Luman, Ph.D. News Read the full press release here. Kimberly J. Miller, Ph.D. Dr. Kim Miller serves as a single point of contact for all IP-related matters her clients face. For more established companies, she easily adapts to their... Agnes Juang, Ph.D. Dr. Agnes Juang provides counsel and advice to innovators seeking to protect their inventions and to grow and monetize their IP assets. Her practice includes... Joseph Mallon, Ph.D. Joe's practice includes intellectual property due diligence, Patent Office appeals, preparation and prosecution of patent applications, and counseling on patent... Ryan E. Melnick, Ph.D. Ryan E. Melnick is a partner in our San Diego Office. Dr. Melnick’s practice focuses on obtaining patent protection and providing counsel to pharmaceutical... William Zimmerman Having served as lead counsel in over 100 pharmaceutical litigations, including cases involving “blockbuster” drugs like Lipitor and Nexium, William R... Jane Dai, Ph.D. With extensive knowledge in organic chemistry, Jane advises clients in life sciences, with a particular focus on small molecule and oligonucleotide... Nathanael Luman, Ph.D. Nathanael R. Luman, Ph.D., represents chemical and pharmaceutical companies in intellectual property matters. He is actively involved in Inter Partes Review...